Evidence map›Paper›PMID 26362774›Full record

Trial reportThe international journal of neuropsychopharmacology2015

The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.

Ewelina Rzepa, Luke Tudge, Ciara McCabe

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. ΔBiological psychiatry. Cognitive neuroscience and neuroimaging · 2026
    Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Individual and combined effects of cannabidiol and ΔJournal of psychopharmacology (Oxford, England) · 2022
    Article
  9. Review
  10. Article
  11. Biomedicines · 2021
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ewelina RzepaSchool of Psychology and Clinical Language Sciences, University of Reading, UK (Ms Rzepa, Mr Tudge, and Dr McCabe); Department of Psychiatry, Warneford Hospital, University of Oxford, UK (Dr McCabe).
Luke TudgeSchool of Psychology and Clinical Language Sciences, University of Reading, UK (Ms Rzepa, Mr Tudge, and Dr McCabe); Department of Psychiatry, Warneford Hospital, University of Oxford, UK (Dr McCabe).
Ciara McCabeSchool of Psychology and Clinical Language Sciences, University of Reading, UK (Ms Rzepa, Mr Tudge, and Dr McCabe); Department of Psychiatry, Warneford Hospital, University of Oxford, UK (Dr McCabe). c.mccabe@reading.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe cannabinoid cannabinoid type 1 (CB1) neutral antagonist tetrahydrocannabivarin (THCv) has been suggested as a possible treatment for obesity, but without the depressogenic side-effects of inverse antagonists such as Rimonabant. However, how THCv might affect the resting state functional connectivity of the human brain is as yet unknown.

methodWe examined the effects of a single 10mg oral dose of THCv and placebo in 20 healthy volunteers in a randomized, within-subject, double-blind design. Using resting state functional magnetic resonance imaging and seed-based connectivity analyses, we selected the amygdala, insula, orbitofrontal cortex, and dorsal medial prefrontal cortex (dmPFC) as regions of interest. Mood and subjective experience were also measured before and after drug administration using self-report scales.

resultsOur results revealed, as expected, no significant differences in the subjective experience with a single dose of THCv. However, we found reduced resting state functional connectivity between the amygdala seed region and the default mode network and increased resting state functional connectivity between the amygdala seed region and the dorsal anterior cingulate cortex and between the dmPFC seed region and the inferior frontal gyrus/medial frontal gyrus. We also found a positive correlation under placebo for the amygdala-precuneus connectivity with the body mass index, although this correlation was not apparent under THCv.

conclusionOur findings are the first to show that treatment with the CB1 neutral antagonist THCv decreases resting state functional connectivity in the default mode network and increases connectivity in the cognitive control network and dorsal visual stream network. This effect profile suggests possible therapeutic activity of THCv for obesity, where functional connectivity has been found to be altered in these regions.

Indexed as

AdultBrainCross-Over StudiesDouble-Blind MethodDronabinolExecutive FunctionFemaleHealthy VolunteersHumansMagnetic Resonance ImagingMaleNerve NetReceptor, Cannabinoid, CB1RestYoung AdultDronabinolReceptor, Cannabinoid, CB1tetrahydrocannabivarin 9Cannabinoidsdefault modefMRIobesityresting statereward

Identifiers

PMID26362774
PMCPMC4772823

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.